NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis → The Long-Awaited End of America Update (From Stansberry Research) (Ad) Free ARTL Stock Alerts $1.38 +0.08 (+6.15%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$1.36▼$1.3950-Day Range$1.28▼$1.5852-Week Range$1.15▼$2.98Volume4,531 shsAverage Volume15,230 shsMarket Capitalization$4.46 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media Get Artelo Biosciences alerts: Email Address Artelo Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside262.3% Upside$5.00 Price TargetShort InterestHealthy0.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.07) to ($1.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 stars 3.5 Analyst's Opinion Consensus RatingArtelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.19% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently decreased by 57.93%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARTL. Previous Next 2.8 News and Social Media Coverage News SentimentArtelo Biosciences has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.Search Interest3 people have searched for ARTL on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.90% of the stock of Artelo Biosciences is held by insiders.Percentage Held by InstitutionsOnly 0.87% of the stock of Artelo Biosciences is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Artelo Biosciences are expected to grow in the coming year, from ($2.07) to ($1.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtelo Biosciences has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Artelo Biosciences Stock (NASDAQ:ARTL)Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Read More ARTL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARTL Stock News HeadlinesApril 23, 2024 | globenewswire.comArtelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer TherapyApril 22, 2024 | globenewswire.comArtelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern TimeMay 2, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.March 25, 2024 | benzinga.comRecap: Artelo Biosciences Q4 EarningsMarch 25, 2024 | msn.comArtelo Biosciences GAAP EPS of -$3.14 misses by $0.58March 25, 2024 | globenewswire.comArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMarch 12, 2024 | globenewswire.comArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation ChallengeFebruary 15, 2024 | finanznachrichten.deArtelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thMay 2, 2024 | The Freeport Society (Ad)New Trump BombshellI believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… January 8, 2024 | finance.yahoo.comArtelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12December 5, 2023 | finance.yahoo.comArtelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyNovember 16, 2023 | markets.businessinsider.comPromising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating RecommendationNovember 13, 2023 | msn.comArtelo Biosciences GAAP EPS of -$0.83 misses by $0.18November 13, 2023 | finance.yahoo.comArtelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 7, 2023 | morningstar.comArtelo Biosciences Inc ARTLNovember 2, 2023 | finance.yahoo.comArtelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023September 5, 2023 | finance.yahoo.comArtelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13thAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)June 28, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.June 27, 2023 | msn.comArtelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic PainJune 27, 2023 | finance.yahoo.comArtelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society SymposiumMay 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)May 11, 2023 | msn.comArtelo Biosciences: Q1 Earnings InsightsMay 11, 2023 | finance.yahoo.comArtelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateApril 25, 2023 | finance.yahoo.comArtelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossApril 4, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Gets a Buy from Maxim GroupApril 3, 2023 | markets.businessinsider.comArtelo Biosciences (ARTL) Gets a Buy from Ladenburg Thalmann & Co.See More Headlines Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/25/2024Today5/02/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ARTL CUSIPN/A CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+259.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,290,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.68% Return on Assets-58.15% Debt Debt-to-Equity RatioN/A Current Ratio8.51 Quick Ratio8.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.12 per share Price / Book0.34Miscellaneous Outstanding Shares3,230,000Free Float3,005,000Market Cap$4.49 million OptionableNot Optionable Beta1.44 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Gregory D. Gorgas M.B.A. (Age 61)President, CEO, CFO, Treasurer, Secretary & Director Comp: $742.45kDr. Andrew Yates Ph.D.Senior VP & Chief Scientific OfficerDr. Steven D. Reich (Age 78)Chief Medical Officer Mr. Jason H. Baybutt (Age 52)Senior Vice President of Finance Key CompetitorsBright Minds BiosciencesNASDAQ:DRUGExicureNASDAQ:XCURPetros PharmaceuticalsNASDAQ:PTPIEnsysce BiosciencesNASDAQ:ENSCChina PharmaNYSE:CPHIView All Competitors ARTL Stock Analysis - Frequently Asked Questions Should I buy or sell Artelo Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Artelo Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARTL shares. View ARTL analyst ratings or view top-rated stocks. What is Artelo Biosciences' stock price target for 2024? 1 Wall Street analysts have issued 12-month price targets for Artelo Biosciences' stock. Their ARTL share price targets range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 262.3% from the stock's current price. View analysts price targets for ARTL or view top-rated stocks among Wall Street analysts. How have ARTL shares performed in 2024? Artelo Biosciences' stock was trading at $1.40 at the start of the year. Since then, ARTL stock has decreased by 1.4% and is now trading at $1.38. View the best growth stocks for 2024 here. Are investors shorting Artelo Biosciences? Artelo Biosciences saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 6,100 shares, a decline of 57.9% from the March 31st total of 14,500 shares. Based on an average daily volume of 14,800 shares, the short-interest ratio is presently 0.4 days. Approximately 0.2% of the shares of the stock are short sold. View Artelo Biosciences' Short Interest. When is Artelo Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ARTL earnings forecast. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) released its quarterly earnings data on Monday, March, 25th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.70. When did Artelo Biosciences' stock split? Artelo Biosciences's stock reverse split on the morning of Wednesday, August 10th 2022. The 1-15 reverse split was announced on Wednesday, August 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Artelo Biosciences investors own include NVIDIA (NVDA), VBI Vaccines (VBIV), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Flexion Therapeutics (FLXN), OPKO Health (OPK), Overstock.com (OSTK), Allena Pharmaceuticals (ALNA) and Advanced Micro Devices (AMD). How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARTL) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithYour bank is lying to you.MyBankTrackerThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingTrump just won 2024Porter & CompanyHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
